This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, C.-Y. Articles by Cheng, A. F. B. Search for Related Content PubMed PubMed Citation Articles by Chan, C.-Y. Articles by Cheng, A. F. B.

In Vitro Postantibiotic Effects of Rifapentine, Isoniazid, and Moxifloxacin against Mycobacterium tuberculosis

Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories,¹ Tuberculosis and Chest Unit, Grantham Hospital, Aberdeen,² Tuberculosis and Chest Service, Department of Health, Hong Kong³

Received 6 August 2003/ Returned for modification 18 August 2003/ Accepted 6 October 2003

Postantibiotic effects (PAEs) of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis ATCC 27294 were studied using a radiometric culture system. Rifapentine at 20 mg/liter gave the longest PAE (104 h) among the drugs used alone. The combinations of rifapentine plus isoniazid, rifapentine plus moxifloxacin, and isoniazid plus moxifloxacin gave PAEs of 136.5, 59.0, and 8.3 h, respectively.

This article has been cited by other articles:

• Reddy, V. M., Einck, L., Nacy, C. A. (2008). In Vitro Antimycobacterial Activities of Capuramycin Analogues. Antimicrob. Agents Chemother. 52: 719-721 [Abstract] [Full Text]  
• Shandil, R. K., Jayaram, R., Kaur, P., Gaonkar, S., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharath, S., Balasubramanian, V. (2007). Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy. Antimicrob. Agents Chemother. 51: 576-582 [Abstract] [Full Text]  
• Sirgel, F. A., Fourie, P. B., Donald, P. R., Padayatchi, N., Rustomjee, R., Levin, J., Roscigno, G., Norman, J., McIlleron, H., Mitchison, D. A., the Rifapentine EBA Collaborative Study Group, (2005). The Early Bactericidal Activities of Rifampin and Rifapentine in Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 172: 128-135 [Abstract] [Full Text]  
• Ginsburg, A. S., Lee, J., Woolwine, S. C., Grosset, J. H., Hamzeh, F. M., Bishai, W. R. (2005). Modeling In Vivo Pharmacokinetics and Pharmacodynamics of Moxifloxacin Therapy for Mycobacterium tuberculosis Infection by Using a Novel Cartridge System. Antimicrob. Agents Chemother. 49: 853-856 [Abstract] [Full Text]